These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20353934)

  • 1. Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status.
    Naeim A; Wong FL; Pal SK; Hurria A
    Clin Breast Cancer; 2010 Apr; 10(2):136-43. PubMed ID: 20353934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists.
    Hurria A; Wong FL; Pal S; Chung CT; Bhatia S; Mortimer J; Somlo G; Hurvitz S; Villaluna D; Naeim A
    Oncologist; 2009 Sep; 14(9):883-90. PubMed ID: 19726455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers.
    Hurria A; Wong FL; Villaluna D; Bhatia S; Chung CT; Mortimer J; Hurvitz S; Naeim A
    J Clin Oncol; 2008 Nov; 26(33):5386-92. PubMed ID: 18955446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
    Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
    Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
    Kurian AW; Bondarenko I; Jagsi R; Friese CR; McLeod MC; Hawley ST; Hamilton AS; Ward KC; Hofer TP; Katz SJ
    J Natl Cancer Inst; 2018 May; 110(5):493-500. PubMed ID: 29237009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
    Tervonen HE; Daniels B; Tang M; Preen DB; Pearson SA
    Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):812-820. PubMed ID: 30861596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists.
    Hurria A; Naeim A; Elkin E; Limaye S; Grover A; Hudis C; Pearce C; Robson M
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):255-60. PubMed ID: 17098441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).
    Gori S; Puglisi F; Cinquini M; Pappagallo G; Frassoldati A; Biganzoli L; Cortesi L; Fiorentino A; Angiolini C; Tinterri C; De Censi A; Levaggi A; Del Mastro L
    Eur J Cancer; 2018 Aug; 99():9-19. PubMed ID: 29886394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: a survey among Italian oncologists.
    Barni S; Collovà E; Frassoldati A; Amoroso D
    Future Oncol; 2015; 11(8):1181-9. PubMed ID: 25832875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimisation of breast cancer patients' follow-up - potential way to improve cancer care in transitional countries.
    Bošković L; Gašparić M; Petrić Miše B; Petković M; Gugić D; Ban M; Jazvić M; Dabelić N; Belac Lovasić I; Vrdoljak E
    Eur J Cancer Care (Engl); 2017 Jul; 26(4):. PubMed ID: 27145728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
    Kim HK; Lee SH; Kim YJ; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Ahn JS; Im YH; Yu JH; Park YH
    BMC Cancer; 2019 Jan; 19(1):84. PubMed ID: 30654765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
    Younus J; Vandenberg TA
    Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study.
    Goldschmidt D; Dalal AA; Romdhani H; Kelkar S; Guerin A; Gauthier G; Wu EQ; Niravath P; Small T
    Adv Ther; 2018 Apr; 35(4):482-493. PubMed ID: 29582246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.
    Albanell J; González A; Ruiz-Borrego M; Alba E; García-Saenz JA; Corominas JM; Burgues O; Furio V; Rojo A; Palacios J; Bermejo B; Martínez-García M; Limon ML; Muñoz AS; Martín M; Tusquets I; Rojo F; Colomer R; Faull I; Lluch A
    Ann Oncol; 2012 Mar; 23(3):625-631. PubMed ID: 21652577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
    Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
    Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.
    Svahn TH; Niland JC; Carlson RW; Hughes ME; Ottesen RA; Theriault RL; Edge SB; Schott AF; Bookman MA; Weeks JC
    J Natl Compr Canc Netw; 2009 Feb; 7(2):115-21. PubMed ID: 19200415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adjuvant chemotherapy of early stage breast cancer].
    Boér K
    Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.